



Press release

Christian de la Tour is promoted Chairman of Ipsen UK and Sean McKercher, Vice-President, Corporate Business Development

Paris (France), 24 February 2009 - Ipsen (Euronext: FR0010259150; IPN) today announced two promotions.

Christian de la Tour is promoted to Chairman, Ipsen UK Companies reporting to the Ipsen Executive Committee upon the forthcoming retirement of Dr Alistair Stokes. He will also support Ipsen's Executive Committee in the coordination of strategic, cross-functional projects and will assume responsibility for the follow-up of Ipsen's spin-off companies. Christian de la Tour was a founder member of the Corporate Business Development department which he has been heading up since 1998. He has been responsible for a number of highly strategic worldwide acquisition, partnering and licensing transactions and agreements for Ipsen.

Sean McKercher succeeds Christian de la Tour as Vice-President, Corporate Business Development, reporting to Stéphane Thiroloix, Executive Vice-President, Corporate Development of Ipsen. He joined Ipsen in 2007 as Vice President, Commercial Development for North America where he was instrumental in spearheading Ipsen's commercial entry into the United States. Prior to joining Ipsen he has over 25 years of leadership experience with pharmaceutical companies operating in Asia, Africa and North America.

Both Christian de la Tour and Sean McKercher will operate out of Ipsen's office in London.

About Ipsen

Ipsen is an innovation-driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,000. Its development strategy is based on a combination of specialty products, which are growth drivers, in targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 700 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. This strategy is also supported by an active policy of partnerships. In 2007, Research and Development expenditure was about €185 million, in excess of 20% of consolidated sales, which amounted to €920.5 million while total revenues amounted to €993.8 million. Ipsen's shares are traded on Segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150). Ipsen's shares are eligible to the "Service de Règlement Différé" ("SRD") and the Group is part of the SBF 120 index. For more information on Ipsen, visit our website at www.ipсен.com



For further information:

Didier Véron

Director, Public Affairs and Corporate Communications

Tel.: +33 (0)1 58 33 51 16

Fax: +33 (0)1 58 33 50 58

E-mail: didier.veron@ipsen.com

David Schilansky

Investor Relations Officer

Tel.: +33 (0)1 58 33 51 30

Fax: +33 (0)1 58 33 50 63

E-mail: david.schilansky@ipsen.com